| Literature DB >> 35694050 |
Chandrika Azad1, Vishal Guglani1, Anam Siddiqui1, Sukhvinder Singh2.
Abstract
Background Children with epilepsy (CWE) are at high risk of psychopathological problems because of neurobiological, social, and treatment factors. Objectives This study was conducted to estimate the prevalence of psychopathological problems in CWE and their contributing factors. Methods This cross-sectional study was done in pediatric neurology clinic and outpatient department of a government medical college in Northern India. Children between the ages of 4 and 14 years with intelligence quotient > 70 were enrolled; for CWE, the criteria were antiepileptic drugs therapy for more than 6 months and for controls it was being free from any chronic illness. Childhood Psychopathology Measurement Schedule (CPMS) was used for assessing psychopathological problems. Results A total of 135 CWE and 70 controls were enrolled, groups were similar in respect of age, gender, socioeconomic status, and family history. CWE group had significantly high mean ± standard deviation CPMS scores (13.68 ± 10.57) as compared with controls (9.75 ± 7.97) ( p < 0.0001). These scores were particularly high in sectors of low intelligence, conduct disorder, psychotic symptoms, and depression. Academic performance was significantly poor in CWE (39%) versus controls (6%) ( p 0.042). Age of onset, duration, type, and etiology of epilepsy had no significant relation with CPMS scores. Polytherapy and treatment with valproate were associated with high CPMS scores ( p 0.005 and 0.045). Conclusion Psychopathological problems are frequently associated with epilepsy in children and antiepileptic drug therapy might contribute to it. Association for Helping Neurosurgical Sick People. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).Entities:
Keywords: antiepileptic drugs; children with epilepsy; psychopathological problems
Year: 2022 PMID: 35694050 PMCID: PMC9187380 DOI: 10.1055/s-0042-1743459
Source DB: PubMed Journal: J Neurosci Rural Pract ISSN: 0976-3155
Sociodemographic details of study groups
|
CWE (
|
Controls (
| ||
|---|---|---|---|
| Age, mean ± SD, y | 9.75 ± 2.91 | 9.68 ± 2.45 | 0.853 |
|
Males,
| 76 (56.2) | 44 (62.8) | 0.365 |
|
Poor socioeconomic status,
| 51 (37.7) | 17 (24.2) | 0.051 |
|
Urban residence,
| 21 (15.5) | 25 (35.7) |
|
|
Migrants/natives,
| 38 (28.1) | 20 (28.5) | 0.949 |
|
Psychiatric illness in family,
| 6 (4.4) | 8 (11.4) | 0.600 |
|
Drug addiction/alcoholism in family,
| 39 (28.8) | 15 (21.4) | 0.250 |
|
Family criminal background,
| 4 (2.9) | 1 (1.4) | 0.500 |
Abbreviations: CWE, children with epilepsy; SD, standard deviation.
Note: p -Values set in bold are statistically significant.
Clinical details of CWE and controls
|
CWE (
|
Controls (
| ||
|---|---|---|---|
|
Developmental delay,
| 11 (8) | 0 (0) | |
|
Poor academic performance,
| 53 (39) | 4 (6) |
|
|
CPMS > 10,
| 72 (53) | 23 (33) |
|
| CPMS, mean ± SD | 13.68 ± 10.57 | 9.75 ± 7.97 |
|
| Low intelligence, mean ± SD | 3.44 ± 2.98 | 1.51 ± 1.98 |
|
| Conduct disorder, mean ± SD | 4.59 ± 4.24 | 3.58 ± 3.38 |
|
| Anxiety, mean ± SD | 0.75 ± 0.97 | 0.80 ± 1.08 | 0.382 |
| Psychotic symptoms, mean ± SD | 0.78 ± 1.22 | 0.51 ± 0.84 |
|
| Depression, mean ± SD | 1.73 ± 1.97 | 1.11 ± 1.90 |
|
| Special symptoms, mean ± SD | 0.68 ± 1.10 | 0.44 ± 0.86 | 0.058 |
| Physical illness, mean ± SD | 0.66 ± 0.84 | 0.50 ± 0.88 | 0.094 |
| Somatization, mean ± SD | 1.03 ± 1.49 | 1.28 ± 1.01 | 0.099 |
Abbreviations: CPMS, Childhood Psychopathology Measurement Schedule; CWE, children with epilepsy; SD, standard deviation.
Note: p -Values set in bold are statistically significant.
Characteristics of children with epilepsy
| Variable |
CPMS ≤ 10 (
|
CPMS > 10 (
| |
|---|---|---|---|
| Age, mean ± SD, y | 9.47 ± 2.62 | 10 ± 3.14 | 0.149 |
|
Males,
| 36 (57) | 40 (55.5) | 0.398 |
|
Poor socioeconomic status,
| 22 (35) | 28 (39) | 0.633 |
|
Urban residence,
| 7 (11) | 14 (19) | 0.151 |
|
Poor academic performance,
| 19 (30) | 34 (47) |
|
| CPMS score, mean ± SD | 6.58 ± 2.39 | 19.88 ± 10.98 |
|
| Age at onset of epilepsy, mean ± SD, y | 6.76 ± 3.28 | 7.11 ± 3.46 | 0.264 |
| Duration of epilepsy, | 32.53 ± 27.25 | 34.60 ± 25.86 | 0.326 |
|
Generalized seizures,
| 34 (54) | 36 (50) | 0.64 |
| Symptomatic epilepsy, n (%) | 33 (52) | 38 (53) | 0.963 |
| Duration of AED, mean ± SD, mo | 27.61 ± 21.48 | 29.80 ± 21.21 | 0.277 |
|
Polytherapy,
| 1 (1.5) | 11 (15) |
|
| Antiepileptic drugs | |||
|
Phenytoin,
| 43 (68) | 34 (47) |
|
|
Sodium valproate,
| 12 (19) | 31 (43) | |
|
Levetiracetam,
| 0 | 4 (5.5) | |
|
Carbamazepine,
| 7 (11) | 11 (15) | |
|
Benzodiazepines,
| 2 (3) | 5 (7) | |
| Seizure recurrence | |||
|
Weekly,
| 3 | 5 | 0.231 |
|
Monthly,
| 2 | 7 | |
|
Yearly/no recurrence,
| 60 | 60 | |
Abbreviations: AED, antiepileptic drug; CPMS, Childhood Psychopathology Measurement Schedule; SD, standard deviation.
Note: p -Values set in bold are statistically significant.
Characteristics of control group
|
CPMS ≤ 10 (
|
CPMS > 10 (
| ||
|---|---|---|---|
| Age, mean ± SD, y | 9.54 ± 2.37 | 9.96 ± 2.65 | 0.253 |
|
Males,
| 27 (57) | 18 (78) | 0.087 |
|
Poor socioeconomic status,
| 12 (25.5) | 6 (26) | 0.567 |
|
Rural residence,
| 32 (68) | 12 (52) | 0.156 |
|
Poor academic performance,
| 2 (4) | 2 (9) | 0.323 |
|
Alcoholism/drug addiction in family,
| 8 (17) | 7 (30) | 0.198 |
|
Psychiatric disorders in family,
| 5 (11) | 3 (13) | 0.766 |
| CPMS score, mean ± SD | 5.25 ± 2.18 | 18.95 ± 7.58 |
|
Abbreviations: CPMS, Childhood Psychopathology Measurement Schedule; SD, standard deviation.
Note: p -Values set in bold are statistically significant.
Predictive factors for poor CPMS score
| CPMS < 10 | CPMS > 10 | Odds ratio | ||
|---|---|---|---|---|
| Socioeconomic class | ||||
|
KS IV/V (
| 34 (50) | 34 (50) | 1.24 (0.69–2.23) | 0.45 |
|
KS I/III (
| 76 (55) | 61 (45) | Ref | |
| Residence | ||||
|
Urban (
| 22 (47) | 25 (53) | 1.42 (0.74–2.74) | 0.28 |
|
Rural (
| 88 (56) | 70 (44) | Ref | |
|
Epilepsy (
| 63 (47) | 72 (53) | 2.33 (1.27–4.27) |
|
|
Control (
| 47 (67) | 23 (33) | Ref | |
|
Polytherapy (
| 01 (8) | 11 (92) | 11.18 (1.40–89.26) |
|
|
Monotherapy (
| 62 (50.4) | 61 (49.6) | Ref | |
|
Sodium valproate (
| 12 (28) | 31 (72) | 3.26 (1.46–7.3) |
|
|
Phenytoin (
| 43 (56) | 34 (44) | Ref | |
Abbreviations: CI, confidence interval; CPMS, Childhood Psychopathology Measurement Schedule; KS, Kuppuswamy scale.
Note: p -Values set in bold are statistically significant.